# Ray Therapeutics, Inc.: Phase 3 study in Retinitis Pigmentosa (RP), Inherited Retinal Diseases (60 participants)

**Score:** 80/100

| Field | Value |
|---|---|
| Sponsor | Ray Therapeutics, Inc. |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | Study to Evaluate the Efficacy of a Single Intravitreal Injection of RTx-015 in Participants With Retinitis Pigmentosa (PERCEPT) |
| NCT ID | NCT07901751 |
| Phase | Phase 3 |
| Status | recruiting |
| Conditions | Retinitis Pigmentosa (RP); Inherited Retinal Diseases |
| Intervention types | drug, other |
| Target enrollment | 60 |
| Site countries | United States |
| Posted | 2026-10-28 |
| Planned start | 2026-10 |
| Event | Newly registered study |
| Event date | 2026-10-28 |

## Why this score
- Posted in the last two weeks.
- Industry sponsor (buys outsourced services).
- Phase 3: multi-site, larger budget.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07901751). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.